» Authors » Michael W Parsons

Michael W Parsons

Explore the profile of Michael W Parsons including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 28
Citations 226
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Barata A, Johnson P, Dhawale T, Newcomb R, Amonoo H, Lavoie M, et al.
Transplant Cell Ther . 2025 Jan; PMID: 39870307
Background: CAR T-cell therapy (CAR-T) is leading to durable responses in patients with cancer but there is concern that cytokine release syndrome (CRS) and neurotoxicity may impact survivors' cognitive function....
2.
Gardner M, Winter S, Stahl F, Gerstner E, Shih H, Sherman J, et al.
J Neurooncol . 2024 Oct; 171(2):351-363. PMID: 39400662
Purpose: Radiation therapy (RT) is an integral treatment component in patients with glioma but associated with neurotoxicity. Proton RT (PRT), as compared with photon RT (XRT), reduces excess radiation to...
3.
Winter S, Gardner M, Karschnia P, Vaios E, Grassberger C, Bussiere M, et al.
Oncologist . 2024 Aug; 29(12):e1748-e1761. PMID: 39126664
Background: Central nervous system (CNS) injury following brain-directed radiotherapy remains a major challenge. Proton radiotherapy (PRT) minimizes radiation to healthy brain, potentially limiting sequelae. We characterized CNS radiotoxicity, including radiation-induced...
4.
Dietrich J, Parsons M, Santarnecchi E
Cancer Res . 2024 Apr; 84(13):2041-2042. PMID: 38657103
Many patients with cancer are at risk of developing cognitive symptoms that often become evident during or after cancer-directed therapy and may have difficulties with attention, concentration, multitasking, executive function,...
5.
Winter S, Vaios E, Shih H, Grassberger C, Parsons M, Gardner M, et al.
Curr Treat Options Oncol . 2023 Sep; 24(11):1524-1549. PMID: 37728819
Central nervous system (CNS) radiotoxicity remains a challenge in neuro-oncology. Dose distribution advantages of protons over photons have prompted increased use of brain-directed proton therapy. While well-recognized among pediatric populations,...
6.
Parsons M, Sabsevitz D
J Neurooncol . 2023 Mar; 162(3):525-533. PMID: 36940053
Purpose: The understanding of cognitive symptoms in patients with IDH-Mutant gliomas (IDH-Mut) is rapidly developing. In this article, we summarize the neuroscientific knowledge base regarding the influence of IDH-Mut tumors...
7.
Park D, Tom M, Chen Y, Tewari S, Ahluwalia M, Yu J, et al.
J Neurooncol . 2022 Apr; 158(3):341-348. PMID: 35486307
Purpose: We sought to evaluate the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in patients with low-grade glioma (LGG). Materials/methods: We included adult patients with LGG who were...
8.
Forst D, Podgurski A, Quain K, Landay S, Anand M, Kaslow-Zieve E, et al.
Support Care Cancer . 2022 Mar; 30(7):5811-5820. PMID: 35353218
Purpose: Caregivers of patients with malignant gliomas are at risk for psychological distress. However, factors associated with distress in this population have not been well described. We conducted a prospective...
9.
Park D, Tom M, Wei W, Tewari S, Ahluwalia M, Yu J, et al.
J Neurooncol . 2022 Jan; 156(3):499-507. PMID: 35064450
Purpose: Low-grade glioma (LGG) exhibits longer median survival than high-grade brain tumors, and thus impact of our therapies on patient quality of life remains a crucial consideration. This study evaluated...
10.
Parsons M, Peters K, Floyd S, Brown P, Wefel J
Neurooncol Adv . 2021 Dec; 3(Suppl 5):v96-v107. PMID: 34859237
Neurocognitive function (NCF) deficits are common in patients with brain metastases, occurring in up to 90% of cases. NCF deficits may be caused by tumor-related factors and/or treatment for the...